KR20020083533A - 복소환 유도체 및 의약 - Google Patents
복소환 유도체 및 의약 Download PDFInfo
- Publication number
- KR20020083533A KR20020083533A KR1020027012917A KR20027012917A KR20020083533A KR 20020083533 A KR20020083533 A KR 20020083533A KR 1020027012917 A KR1020027012917 A KR 1020027012917A KR 20027012917 A KR20027012917 A KR 20027012917A KR 20020083533 A KR20020083533 A KR 20020083533A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- group
- alkyl
- substituted
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title description 16
- 229940079593 drug Drugs 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 232
- -1 nitro, hydroxy Chemical group 0.000 claims abstract description 72
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 61
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 43
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 24
- 150000002367 halogens Chemical class 0.000 claims abstract description 24
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 17
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims abstract description 13
- 125000002993 cycloalkylene group Chemical group 0.000 claims abstract description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 11
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims abstract description 9
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 8
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 15
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims description 15
- 239000000730 antalgic agent Substances 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 claims description 6
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 125000006294 amino alkylene group Chemical group 0.000 claims description 4
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- KMLUBVZGTQLNRK-QNCHGCKQSA-N 4-chloro-n-[4-[[(1r,2s)-2-(diaminomethylideneamino)cyclohexyl]amino]-6-methoxyquinazolin-2-yl]benzamide;dihydrochloride Chemical compound Cl.Cl.N1=C(N[C@H]2[C@H](CCCC2)N=C(N)N)C2=CC(OC)=CC=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 KMLUBVZGTQLNRK-QNCHGCKQSA-N 0.000 claims description 3
- 125000005650 substituted phenylene group Chemical group 0.000 claims description 3
- RVNUEBBCFRLWHL-KZJIUNCISA-N 2-[(1s,2r)-2-[[2-[(z)-2-(4-chlorophenyl)ethenyl]-6-methoxyquinazolin-4-yl]amino]cyclohexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(N[C@H]2[C@H](CCCC2)N=C(N)N)C2=CC(OC)=CC=C2N=C1\C=C/C1=CC=C(Cl)C=C1 RVNUEBBCFRLWHL-KZJIUNCISA-N 0.000 claims description 2
- UJOCZXHYKLJJJB-UHFFFAOYSA-N 2-[6-[[6-methoxy-2-(2-pyridin-2-ylethenyl)quinazolin-4-yl]amino]hexyl]guanidine;trihydrochloride Chemical compound Cl.Cl.Cl.N1=C(NCCCCCCNC(N)=N)C2=CC(OC)=CC=C2N=C1C=CC1=CC=CC=N1 UJOCZXHYKLJJJB-UHFFFAOYSA-N 0.000 claims description 2
- OCBSXEUWBMDOEQ-UHFFFAOYSA-N 2-[6-[[6-methyl-2-(2-pyridin-2-ylethenyl)quinazolin-4-yl]amino]hexyl]guanidine;trihydrochloride Chemical compound Cl.Cl.Cl.N1=C(NCCCCCCNC(N)=N)C2=CC(C)=CC=C2N=C1C=CC1=CC=CC=N1 OCBSXEUWBMDOEQ-UHFFFAOYSA-N 0.000 claims description 2
- RWMMBMNJAIPOKT-UHFFFAOYSA-N 2-phenylethanamine trihydrochloride Chemical compound Cl.Cl.Cl.C1(=CC=CC=C1)CCN RWMMBMNJAIPOKT-UHFFFAOYSA-N 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 10
- 102100028646 Nociceptin receptor Human genes 0.000 abstract description 9
- 108010020615 nociceptin receptor Proteins 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 5
- 208000000094 Chronic Pain Diseases 0.000 abstract description 4
- 208000004454 Hyperalgesia Diseases 0.000 abstract description 4
- 208000007514 Herpes zoster Diseases 0.000 abstract description 3
- 206010053552 allodynia Diseases 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 112
- 239000000243 solution Substances 0.000 description 111
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 75
- 238000000034 method Methods 0.000 description 70
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 68
- 125000002091 cationic group Chemical group 0.000 description 67
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 67
- 239000002904 solvent Substances 0.000 description 64
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 46
- 238000000921 elemental analysis Methods 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 239000000843 powder Substances 0.000 description 42
- 239000000203 mixture Substances 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 238000010898 silica gel chromatography Methods 0.000 description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 238000009835 boiling Methods 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 150000001412 amines Chemical class 0.000 description 17
- 238000000605 extraction Methods 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 238000001035 drying Methods 0.000 description 16
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 8
- 235000011054 acetic acid Nutrition 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 239000012300 argon atmosphere Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 239000004210 ether based solvent Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- KMLUBVZGTQLNRK-DPSPSOFVSA-N 4-chloro-n-[4-[[(1s,2r)-2-(diaminomethylideneamino)cyclohexyl]amino]-6-methoxyquinazolin-2-yl]benzamide;dihydrochloride Chemical compound Cl.Cl.N1=C(N[C@@H]2[C@@H](CCCC2)N=C(N)N)C2=CC(OC)=CC=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 KMLUBVZGTQLNRK-DPSPSOFVSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- BDLPJHZUTLGFON-UHFFFAOYSA-N tert-butyl n-(6-hydroxyhexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCO BDLPJHZUTLGFON-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- DRNGLYHKYPNTEA-UHFFFAOYSA-N 4-azaniumylcyclohexane-1-carboxylate Chemical compound NC1CCC(C(O)=O)CC1 DRNGLYHKYPNTEA-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102400001111 Nociceptin Human genes 0.000 description 3
- 108090000622 Nociceptin Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- AKVIZYGPJIWKOS-DTWKUNHWSA-N tert-butyl n-[(1r,2s)-2-aminocyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCC[C@@H]1N AKVIZYGPJIWKOS-DTWKUNHWSA-N 0.000 description 3
- AKVIZYGPJIWKOS-BDAKNGLRSA-N tert-butyl n-[(1s,2r)-2-aminocyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCC[C@H]1N AKVIZYGPJIWKOS-BDAKNGLRSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- RVNUEBBCFRLWHL-DDZPGPNZSA-N 2-[(1r,2s)-2-[[2-[2-(4-chlorophenyl)ethenyl]-6-methoxyquinazolin-4-yl]amino]cyclohexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(N[C@@H]2[C@@H](CCCC2)N=C(N)N)C2=CC(OC)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 RVNUEBBCFRLWHL-DDZPGPNZSA-N 0.000 description 2
- CNYAKFZBCOWUDC-UHFFFAOYSA-N 2-[6-[[2-[2-(4-chlorophenyl)ethenyl]-6-methylquinazolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCCCCCCNC(N)=N)C2=CC(C)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 CNYAKFZBCOWUDC-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- JXRBVNNNVAFQDN-HDJSIYSDSA-N CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CNC(=O)OC(C)(C)C)CC1 Chemical compound CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CNC(=O)OC(C)(C)C)CC1 JXRBVNNNVAFQDN-HDJSIYSDSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- OIJXLIIMXHRJJH-ZXJLXYCOSA-N [3h]diprenorphine Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@]22C[C@@H]([C@]3(OC)CC2)C(C)(C)O)C([3H])C1[3H])CC1CC1 OIJXLIIMXHRJJH-ZXJLXYCOSA-N 0.000 description 2
- YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000005456 alcohol based solvent Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- LHQRDAIAWDPZGH-UHFFFAOYSA-N cyclohexylhydrazine Chemical compound NNC1CCCCC1 LHQRDAIAWDPZGH-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LNGAGQAGYITKCW-UHFFFAOYSA-N dimethyl cyclohexane-1,4-dicarboxylate Chemical compound COC(=O)C1CCC(C(=O)OC)CC1 LNGAGQAGYITKCW-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- RKOQMDUDKCMVFW-UHFFFAOYSA-N methyl 4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexane-1-carboxylate Chemical compound COC(=O)C1CCC(NC(=O)OC(C)(C)C)CC1 RKOQMDUDKCMVFW-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- AKMUXRHTWYTBRB-UHFFFAOYSA-N n-[(4-aminocyclohexyl)methyl]-2,2,2-trifluoroacetamide Chemical compound NC1CCC(CNC(=O)C(F)(F)F)CC1 AKMUXRHTWYTBRB-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- GDKYNMQBGVLYPS-UHFFFAOYSA-N tert-butyl 1-carbamimidoylpyrazole-3-carboxylate Chemical compound CC(C)(C)OC(=O)C=1C=CN(C(N)=N)N=1 GDKYNMQBGVLYPS-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LGQYRVQKKHRMNB-UHFFFAOYSA-N tert-butyl n-(6-aminoheptyl)carbamate Chemical compound CC(N)CCCCCNC(=O)OC(C)(C)C LGQYRVQKKHRMNB-UHFFFAOYSA-N 0.000 description 2
- FJMAIZKRMSRGHG-UHFFFAOYSA-N tert-butyl n-(6-hydroxyheptyl)carbamate Chemical compound CC(O)CCCCCNC(=O)OC(C)(C)C FJMAIZKRMSRGHG-UHFFFAOYSA-N 0.000 description 2
- XVROWZPERFUOCE-RKDXNWHRSA-N tert-butyl n-[(1r,2r)-2-hydroxycyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCC[C@H]1O XVROWZPERFUOCE-RKDXNWHRSA-N 0.000 description 2
- MOYILOWCZPYTQW-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-2-phenylmethoxycyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCC[C@H]1OCC1=CC=CC=C1 MOYILOWCZPYTQW-HZPDHXFCSA-N 0.000 description 2
- NPFQKJGOPNBNCU-JKSUJKDBSA-N tert-butyl n-[(1r,2s)-2-[(2-chloro-6-methoxyquinazolin-4-yl)amino]cyclohexyl]carbamate Chemical compound C12=CC(OC)=CC=C2N=C(Cl)N=C1N[C@H]1CCCC[C@H]1NC(=O)OC(C)(C)C NPFQKJGOPNBNCU-JKSUJKDBSA-N 0.000 description 2
- SGNKPJPMWHKOJO-UHFFFAOYSA-N tert-butyl n-[4-(hydroxymethyl)cyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(CO)CC1 SGNKPJPMWHKOJO-UHFFFAOYSA-N 0.000 description 2
- QFNFDHNZVTWZED-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1C=CC=N1 QFNFDHNZVTWZED-UHFFFAOYSA-N 0.000 description 2
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- AKVIZYGPJIWKOS-RKDXNWHRSA-N (1R,2R)-trans-N-Boc-1,2-cyclohexanediamine Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCC[C@H]1N AKVIZYGPJIWKOS-RKDXNWHRSA-N 0.000 description 1
- NTHNRYLIXJZHRZ-CHWSQXEVSA-N (1r,2r)-2-phenylmethoxycyclohexan-1-amine Chemical compound N[C@@H]1CCCC[C@H]1OCC1=CC=CC=C1 NTHNRYLIXJZHRZ-CHWSQXEVSA-N 0.000 description 1
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- PXGZQGDTEZPERC-UHFFFAOYSA-N 1,4-cyclohexanedicarboxylic acid Chemical compound OC(=O)C1CCC(C(O)=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- PFMLKZTUFFFJOS-YUMKVYMKSA-N 1-amino-1-[(1R,2S)-2-[6-methoxy-2-[(Z)-2-pyridin-3-ylethenyl]quinazolin-4-yl]cyclohexyl]guanidine trihydrochloride Chemical compound Cl.Cl.Cl.N1=C([C@@H]2[C@@H](CCCC2)N(N)C(N)=N)C2=CC(OC)=CC=C2N=C1\C=C/C1=CC=CN=C1 PFMLKZTUFFFJOS-YUMKVYMKSA-N 0.000 description 1
- WSHZXAKBZYJLTH-UHFFFAOYSA-N 1-hexyl-3-phenylthiourea Chemical compound CCCCCCNC(=S)NC1=CC=CC=C1 WSHZXAKBZYJLTH-UHFFFAOYSA-N 0.000 description 1
- WEAMQTSRMCCGSJ-UHFFFAOYSA-N 2,4-dichloro-6-methoxyquinazoline Chemical compound N1=C(Cl)N=C(Cl)C2=CC(OC)=CC=C21 WEAMQTSRMCCGSJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MPRLNCSLKHFNKV-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)ethenyl]-4-(4-pyrimidin-2-ylpiperazin-1-yl)quinazoline;dihydrochloride Chemical compound Cl.Cl.C1=CC(Cl)=CC=C1C=CC1=NC(N2CCN(CC2)C=2N=CC=CN=2)=C(C=CC=C2)C2=N1 MPRLNCSLKHFNKV-UHFFFAOYSA-N 0.000 description 1
- BRKKWQXIUNXPNE-UHFFFAOYSA-N 2-[2-[3-[[6-methyl-2-(2-pyridin-2-ylethenyl)quinazolin-4-yl]amino]propoxy]ethyl]guanidine;trihydrochloride Chemical compound Cl.Cl.Cl.N1=C(NCCCOCCN=C(N)N)C2=CC(C)=CC=C2N=C1C=CC1=CC=CC=N1 BRKKWQXIUNXPNE-UHFFFAOYSA-N 0.000 description 1
- CMRRTGSWMNARKP-UHFFFAOYSA-N 2-[3-[[2-[2-(4-chlorophenyl)ethenyl]quinazolin-4-yl]amino]propyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N=1C2=CC=CC=C2C(NCCCNC(=N)N)=NC=1C=CC1=CC=C(Cl)C=C1 CMRRTGSWMNARKP-UHFFFAOYSA-N 0.000 description 1
- NQCFPCMOELGJES-UHFFFAOYSA-N 2-[4-[[2-[2-(4-chlorophenyl)ethenyl]-6-methylquinazolin-4-yl]amino]butyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCCCCNC(N)=N)C2=CC(C)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 NQCFPCMOELGJES-UHFFFAOYSA-N 0.000 description 1
- ALWMRPSTUYMKJO-UHFFFAOYSA-N 2-[4-[[2-[2-(4-chlorophenyl)ethenyl]quinazolin-4-yl]amino]butyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N=1C2=CC=CC=C2C(NCCCCNC(=N)N)=NC=1C=CC1=CC=C(Cl)C=C1 ALWMRPSTUYMKJO-UHFFFAOYSA-N 0.000 description 1
- FFYOMENEUDONEB-UHFFFAOYSA-N 2-[5-[[2-[2-(4-chlorophenyl)ethenyl]-6,7-dimethylquinazolin-4-yl]amino]pentyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N=1C(NCCCCCNC(N)=N)=C2C=C(C)C(C)=CC2=NC=1C=CC1=CC=C(Cl)C=C1 FFYOMENEUDONEB-UHFFFAOYSA-N 0.000 description 1
- GTXFKEZQJQFZEK-UHFFFAOYSA-N 2-[5-[[2-[2-(4-chlorophenyl)ethenyl]-6-methylquinazolin-4-yl]amino]pentyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCCCCCNC(N)=N)C2=CC(C)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 GTXFKEZQJQFZEK-UHFFFAOYSA-N 0.000 description 1
- CEOUOTAIWATQBX-UHFFFAOYSA-N 2-[5-[[2-[2-(4-chlorophenyl)ethenyl]quinazolin-4-yl]amino]pentyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N=1C2=CC=CC=C2C(NCCCCCNC(=N)N)=NC=1C=CC1=CC=C(Cl)C=C1 CEOUOTAIWATQBX-UHFFFAOYSA-N 0.000 description 1
- WTYSMFDIGIPBPR-UHFFFAOYSA-N 2-[6-[[2-[2-(4-chlorophenyl)ethenyl]-6-methoxyquinazolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCCCCCCNC(N)=N)C2=CC(OC)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 WTYSMFDIGIPBPR-UHFFFAOYSA-N 0.000 description 1
- LTEYTGPWQMYIJH-UHFFFAOYSA-N 2-[6-[[2-[2-(4-chlorophenyl)ethenyl]-6-propan-2-ylquinazolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCCCCCCNC(N)=N)C2=CC(C(C)C)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 LTEYTGPWQMYIJH-UHFFFAOYSA-N 0.000 description 1
- GLSDNBKZWRIOQV-UHFFFAOYSA-N 2-[6-[[2-[2-(4-chlorophenyl)ethenyl]benzo[g]quinazolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N=1C2=CC3=CC=CC=C3C=C2C(NCCCCCCNC(=N)N)=NC=1C=CC1=CC=C(Cl)C=C1 GLSDNBKZWRIOQV-UHFFFAOYSA-N 0.000 description 1
- KMZKTNJUYLDXOX-UHFFFAOYSA-N 2-[6-[[2-[2-(4-chlorophenyl)ethenyl]quinazolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N=1C2=CC=CC=C2C(NCCCCCCNC(=N)N)=NC=1C=CC1=CC=C(Cl)C=C1 KMZKTNJUYLDXOX-UHFFFAOYSA-N 0.000 description 1
- JTZUCWACBXLWEM-UHFFFAOYSA-N 2-[6-[[2-[2-(4-chlorophenyl)ethenyl]quinolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N=1C2=CC=CC=C2C(NCCCCCCNC(=N)N)=CC=1C=CC1=CC=C(Cl)C=C1 JTZUCWACBXLWEM-UHFFFAOYSA-N 0.000 description 1
- XUYWFYWDBWTAQY-UHFFFAOYSA-N 2-[6-[[6-methoxy-2-(2-pyridin-2-ylethenyl)quinazolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCCCCCCNC(N)=N)C2=CC(OC)=CC=C2N=C1C=CC1=CC=CC=N1 XUYWFYWDBWTAQY-UHFFFAOYSA-N 0.000 description 1
- QCJCKPSTJLBVRC-UHFFFAOYSA-N 2-[6-[[6-tert-butyl-2-[2-(4-chlorophenyl)ethenyl]quinazolin-4-yl]amino]hexyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCCCCCCNC(N)=N)C2=CC(C(C)(C)C)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 QCJCKPSTJLBVRC-UHFFFAOYSA-N 0.000 description 1
- MZUYWOQKWVKCCN-UHFFFAOYSA-N 2-[8-[[6-methyl-2-(2-pyridin-2-ylethenyl)quinazolin-4-yl]amino]octyl]guanidine;trihydrochloride Chemical compound Cl.Cl.Cl.N1=C(NCCCCCCCCNC(N)=N)C2=CC(C)=CC=C2N=C1C=CC1=CC=CC=N1 MZUYWOQKWVKCCN-UHFFFAOYSA-N 0.000 description 1
- BLASYCJRHLOVSH-UHFFFAOYSA-N 2-[[4-[[[2-[2-(4-chlorophenyl)ethenyl]-6-methylquinazolin-4-yl]amino]methyl]cyclohexyl]methyl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1=C(NCC2CCC(CNC(N)=N)CC2)C2=CC(C)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 BLASYCJRHLOVSH-UHFFFAOYSA-N 0.000 description 1
- AMZSYPVNYBMNAU-UHFFFAOYSA-N 2-[[4-[[[2-[2-(4-chlorophenyl)ethenyl]quinazolin-4-yl]amino]methyl]cyclohexyl]methyl]guanidine;dihydrochloride Chemical compound Cl.Cl.C1CC(CNC(=N)N)CCC1CNC1=NC(C=CC=2C=CC(Cl)=CC=2)=NC2=CC=CC=C12 AMZSYPVNYBMNAU-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VDFALRUKZDXJCN-UHFFFAOYSA-N 4-chloro-2-[2-(4-chlorophenyl)ethenyl]-6-methoxyquinazoline Chemical compound N1=C(Cl)C2=CC(OC)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 VDFALRUKZDXJCN-UHFFFAOYSA-N 0.000 description 1
- POGDZKKREAOPSA-UHFFFAOYSA-N 4-chloro-6-methoxy-2-(2-pyridin-2-ylethenyl)quinazoline Chemical compound N1=C(Cl)C2=CC(OC)=CC=C2N=C1C=CC1=CC=CC=N1 POGDZKKREAOPSA-UHFFFAOYSA-N 0.000 description 1
- BLNVISNJTIRAHF-UHFFFAOYSA-N 4-chlorobenzamide Chemical compound NC(=O)C1=CC=C(Cl)C=C1 BLNVISNJTIRAHF-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- LOMPNXDREJPCDV-UHFFFAOYSA-N 4-n-[2-[2-(4-chlorophenyl)ethenyl]-6-methylquinazolin-4-yl]cyclohexane-1,4-diamine Chemical compound N1=C(NC2CCC(N)CC2)C2=CC(C)=CC=C2N=C1C=CC1=CC=C(Cl)C=C1 LOMPNXDREJPCDV-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NYXOBVVHJZENCO-XYPYZODXSA-N CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CN)CC1 Chemical compound CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CN)CC1 NYXOBVVHJZENCO-XYPYZODXSA-N 0.000 description 1
- FEYLUKDSKVSMSZ-KYZUINATSA-N CC(C)(C)OC(=O)N[C@H]1CC[C@H](N)CC1 Chemical compound CC(C)(C)OC(=O)N[C@H]1CC[C@H](N)CC1 FEYLUKDSKVSMSZ-KYZUINATSA-N 0.000 description 1
- PQOHSVAMVGYZTC-IYARVYRRSA-N COC(C=C12)=CC=C1N=C(C=CC1=NC=CC=C1)N=C2NC[C@H]1CC[C@H](CNC(N)=N)CC1 Chemical compound COC(C=C12)=CC=C1N=C(C=CC1=NC=CC=C1)N=C2NC[C@H]1CC[C@H](CNC(N)=N)CC1 PQOHSVAMVGYZTC-IYARVYRRSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- OFUMUDFMOABSEG-FFUVTKDNSA-N Cl.Cl.C(N)(=N)N([C@@H]1C[C@H](CCC1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=CC=C(C=C1)Cl)N Chemical compound Cl.Cl.C(N)(=N)N([C@@H]1C[C@H](CCC1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=CC=C(C=C1)Cl)N OFUMUDFMOABSEG-FFUVTKDNSA-N 0.000 description 1
- FQLRUWOJBKFIDE-KJHBKDRRSA-N Cl.Cl.C(N)(=N)N([C@@H]1[C@@H](CCC1)C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=CC=C(C=C1)Cl)N Chemical compound Cl.Cl.C(N)(=N)N([C@@H]1[C@@H](CCC1)C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=CC=C(C=C1)Cl)N FQLRUWOJBKFIDE-KJHBKDRRSA-N 0.000 description 1
- BMOUDERNHQPQLD-UITHODHBSA-N Cl.Cl.C(N)(=N)N([C@@H]1[C@@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=CC=C(C=C1)Cl)N Chemical compound Cl.Cl.C(N)(=N)N([C@@H]1[C@@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=CC=C(C=C1)Cl)N BMOUDERNHQPQLD-UITHODHBSA-N 0.000 description 1
- FQLRUWOJBKFIDE-RHXOVYDGSA-N Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCC1)C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=CC=C(C=C1)Cl)N Chemical compound Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCC1)C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=CC=C(C=C1)Cl)N FQLRUWOJBKFIDE-RHXOVYDGSA-N 0.000 description 1
- BMOUDERNHQPQLD-GQYJSNKSSA-N Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=CC=C(C=C1)Cl)N Chemical compound Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=CC=C(C=C1)Cl)N BMOUDERNHQPQLD-GQYJSNKSSA-N 0.000 description 1
- DIBOJBBQVFISEU-GQYJSNKSSA-N Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=CC=C(C=C1)Cl)N Chemical compound Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=CC=C(C=C1)Cl)N DIBOJBBQVFISEU-GQYJSNKSSA-N 0.000 description 1
- HFFWDNNRTUNTNN-UHFFFAOYSA-N Cl.Cl.Cl.C(N)(=N)N(CC(C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=NC=CC=C1)C1=CC=CC=C1)CCN Chemical compound Cl.Cl.Cl.C(N)(=N)N(CC(C1=NC(=NC2=CC=C(C=C12)OC)C=CC1=NC=CC=C1)C1=CC=CC=C1)CCN HFFWDNNRTUNTNN-UHFFFAOYSA-N 0.000 description 1
- OQZVHFMBOXSAGW-UHFFFAOYSA-N Cl.Cl.Cl.C(N)(=N)N(CC1=CC=C(C=C1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=NC=CC=C1)CN Chemical compound Cl.Cl.Cl.C(N)(=N)N(CC1=CC=C(C=C1)C1=NC(=NC2=CC=C(C=C12)C)C=CC1=NC=CC=C1)CN OQZVHFMBOXSAGW-UHFFFAOYSA-N 0.000 description 1
- GALPDISVRIVGGE-LTVKSBECSA-N Cl.Cl.Cl.C(N)(=N)N([C@@H]1[C@@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)OC)\C=C/C1=NC=CC=C1)N Chemical compound Cl.Cl.Cl.C(N)(=N)N([C@@H]1[C@@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)OC)\C=C/C1=NC=CC=C1)N GALPDISVRIVGGE-LTVKSBECSA-N 0.000 description 1
- GALPDISVRIVGGE-OHXDRLKFSA-N Cl.Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)OC)\C=C/C1=NC=CC=C1)N Chemical compound Cl.Cl.Cl.C(N)(=N)N([C@H]1[C@H](CCCC1)C1=NC(=NC2=CC=C(C=C12)OC)\C=C/C1=NC=CC=C1)N GALPDISVRIVGGE-OHXDRLKFSA-N 0.000 description 1
- JJNYRELAHOEJDY-UHFFFAOYSA-N Cl.Cl.Cl.N(C(=N)N)C(CON(C1=NC(=NC2=CC=C(C=C12)C)C=CC1=NC=CC=C1)CC)C Chemical compound Cl.Cl.Cl.N(C(=N)N)C(CON(C1=NC(=NC2=CC=C(C=C12)C)C=CC1=NC=CC=C1)CC)C JJNYRELAHOEJDY-UHFFFAOYSA-N 0.000 description 1
- UUTWXIJQZHKIHB-UHFFFAOYSA-N Cl.Cl.Cl.N(C(=N)N)CCON(C1=NC(=NC2=CC=C(C=C12)C)C=CC1=NC=CC=C1)CC Chemical compound Cl.Cl.Cl.N(C(=N)N)CCON(C1=NC(=NC2=CC=C(C=C12)C)C=CC1=NC=CC=C1)CC UUTWXIJQZHKIHB-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 101500026210 Homo sapiens Nociceptin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000005725 cyclohexenylene group Chemical group 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- OASMNUIVJWKRRP-UHFFFAOYSA-N cyclohexylhydrazine;dihydrochloride Chemical compound Cl.Cl.NNC1CCCCC1 OASMNUIVJWKRRP-UHFFFAOYSA-N 0.000 description 1
- 125000004978 cyclooctylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- UFMVNSFONAZFOT-UHFFFAOYSA-N dichloromethane;n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound ClCCl.CCN(C(C)C)C(C)C UFMVNSFONAZFOT-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- JMQGGPRJQOQKRT-UHFFFAOYSA-N diphenyl hydrogen phosphate;azide Chemical compound [N-]=[N+]=[N-].C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 JMQGGPRJQOQKRT-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BKBKGEHZTOGPIC-UHFFFAOYSA-N ethyl 4-chloro-6-methoxyquinazoline-2-carboxylate Chemical compound C1=C(OC)C=CC2=NC(C(=O)OCC)=NC(Cl)=C21 BKBKGEHZTOGPIC-UHFFFAOYSA-N 0.000 description 1
- JMIAPORGEDIDLT-UHFFFAOYSA-N ethyl ethanimidate Chemical compound CCOC(C)=N JMIAPORGEDIDLT-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
- 229950010274 lofentanil Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- UCVIJKUSNFFFAY-UHFFFAOYSA-N methyl N'-hexyl-N-phenylcarbamimidothioate Chemical compound C(CCCCC)NC(SC)=NC1=CC=CC=C1 UCVIJKUSNFFFAY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- RBKGITMPXMSJAX-UHFFFAOYSA-N n'-[2-[2-(4-chlorophenyl)ethenyl]quinazolin-4-yl]ethane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.N=1C2=CC=CC=C2C(NCCN)=NC=1C=CC1=CC=C(Cl)C=C1 RBKGITMPXMSJAX-UHFFFAOYSA-N 0.000 description 1
- NPPXHUXMBAZDLT-UHFFFAOYSA-N n'-[6-methoxy-2-(2-pyridin-2-ylethenyl)quinazolin-4-yl]hexane-1,6-diamine Chemical compound N1=C(NCCCCCCN)C2=CC(OC)=CC=C2N=C1C=CC1=CC=CC=N1 NPPXHUXMBAZDLT-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- AKXCFAYOTIEFOH-XTNAHFASSA-N n-[(e)-[(4r,4as,7ar,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ylidene]amino]benzamide Chemical compound C1(/[C@H]2[C@]34CCN(CC=C)[C@@H]([C@@]4(CC1)O)CC1=CC=C(C(O2)=C13)O)=N\NC(=O)C1=CC=CC=C1 AKXCFAYOTIEFOH-XTNAHFASSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- IRUJRVAXEALDLJ-UHFFFAOYSA-N tert-butyl 4-[2-(methylamino)ethyl]piperazine-1-carboxylate Chemical compound CNCCN1CCN(C(=O)OC(C)(C)C)CC1 IRUJRVAXEALDLJ-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- ZFQWJXFJJZUVPI-UHFFFAOYSA-N tert-butyl n-(4-aminobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCN ZFQWJXFJJZUVPI-UHFFFAOYSA-N 0.000 description 1
- RVZPDKXEHIRFPM-UHFFFAOYSA-N tert-butyl n-(6-aminohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN RVZPDKXEHIRFPM-UHFFFAOYSA-N 0.000 description 1
- DTJYPERGUPPXRU-UHFFFAOYSA-N tert-butyl n-(7-aminoheptyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCCN DTJYPERGUPPXRU-UHFFFAOYSA-N 0.000 description 1
- BEHVGNKIRNVBPF-UHFFFAOYSA-N tert-butyl n-(8-aminooctyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCCCN BEHVGNKIRNVBPF-UHFFFAOYSA-N 0.000 description 1
- VWOVVZWSGCHNCI-BJKOFHAPSA-N tert-butyl n-[(1r,2s)-2-[[6-methoxy-2-[(4-methoxyphenyl)methylamino]quinazolin-4-yl]amino]cyclohexyl]carbamate Chemical compound C1=CC(OC)=CC=C1CNC1=NC(N[C@@H]2[C@@H](CCCC2)NC(=O)OC(C)(C)C)=C(C=C(OC)C=C2)C2=N1 VWOVVZWSGCHNCI-BJKOFHAPSA-N 0.000 description 1
- PAXDIBGWURAVIH-JGVFFNPUSA-N tert-butyl n-[(1r,2s)-2-aminocyclopentyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCC[C@@H]1N PAXDIBGWURAVIH-JGVFFNPUSA-N 0.000 description 1
- PAXDIBGWURAVIH-SFYZADRCSA-N tert-butyl n-[(1s,2r)-2-aminocyclopentyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCC[C@H]1N PAXDIBGWURAVIH-SFYZADRCSA-N 0.000 description 1
- OBSACSBMTRJNPH-IUCAKERBSA-N tert-butyl n-[(1s,3s)-3-aminocyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCC[C@H](N)C1 OBSACSBMTRJNPH-IUCAKERBSA-N 0.000 description 1
- ZYSURDPTHWVESU-RBUKOAKNSA-N tert-butyl n-[n'-[(1r,2s)-2-[(2-amino-6-methoxyquinazolin-4-yl)amino]cyclohexyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate Chemical compound C12=CC(OC)=CC=C2N=C(N)N=C1N[C@H]1CCCC[C@H]1NC(NC(=O)OC(C)(C)C)=NC(=O)OC(C)(C)C ZYSURDPTHWVESU-RBUKOAKNSA-N 0.000 description 1
- VJTFVESJYZUCHP-LOSJGSFVSA-N tert-butyl n-[n'-[(1r,2s)-2-[[2-[(4-chlorobenzoyl)amino]-6-methoxyquinazolin-4-yl]amino]cyclohexyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]carbamate Chemical compound N1=C(N[C@@H]2[C@@H](CCCC2)NC(NC(=O)OC(C)(C)C)=NC(=O)OC(C)(C)C)C2=CC(OC)=CC=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 VJTFVESJYZUCHP-LOSJGSFVSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000098874 | 2000-03-31 | ||
| JPJP-P-2000-00098874 | 2000-03-31 | ||
| JP2000336464 | 2000-11-02 | ||
| JPJP-P-2000-00336464 | 2000-11-02 | ||
| PCT/JP2001/002822 WO2001072710A1 (en) | 2000-03-31 | 2001-03-30 | Heterocycle derivatives and drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20020083533A true KR20020083533A (ko) | 2002-11-02 |
Family
ID=26589216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027012917A Withdrawn KR20020083533A (ko) | 2000-03-31 | 2001-03-30 | 복소환 유도체 및 의약 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6794389B2 (enExample) |
| EP (1) | EP1306372B1 (enExample) |
| KR (1) | KR20020083533A (enExample) |
| CN (1) | CN1242993C (enExample) |
| AT (1) | ATE449084T1 (enExample) |
| AU (1) | AU2001244688A1 (enExample) |
| CA (1) | CA2403605A1 (enExample) |
| DE (1) | DE60140545D1 (enExample) |
| RU (1) | RU2268260C2 (enExample) |
| WO (1) | WO2001072710A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL359918A1 (en) * | 2000-09-20 | 2004-09-06 | Merck Patent Gmbh | 4-amino-quinazolines |
| DE60132484T2 (de) | 2000-11-02 | 2009-01-15 | Nippon Shinyaku Co., Ltd. | Chinazolinderivate und -arzneimittel |
| CN1509184A (zh) * | 2001-03-19 | 2004-06-30 | �ձ���ҩ��ʽ���� | 止痒剂 |
| US6907295B2 (en) * | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
| US7829566B2 (en) * | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| KR20040106391A (ko) * | 2002-04-26 | 2004-12-17 | 니뽄 신야쿠 가부시키가이샤 | 퀴나졸린 유도체 및 의약 |
| JP4805234B2 (ja) * | 2002-12-16 | 2011-11-02 | キッセイ薬品工業株式会社 | 経口固形医薬 |
| AU2004253967B2 (en) | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| JP2007524673A (ja) * | 2004-01-23 | 2007-08-30 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドと治療におけるその使用 |
| EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| EP1944298B1 (en) * | 2005-10-03 | 2013-01-09 | Nippon Shinyaku Co., Ltd. | Quinazoline derivative and pharmaceutical |
| RU2314295C2 (ru) * | 2006-03-01 | 2008-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | 2-гетарилзамещенные 1,3-трополона, способ их получения (варианты) и фармацевтическая композиция антимикробного действия |
| CA2685888A1 (en) * | 2007-05-09 | 2008-11-20 | Pfizer Inc. | Substituted heterocyclic derivatives and their pharmaceutical use and compositions |
| EP2017294A1 (de) | 2007-07-16 | 2009-01-21 | Sika Technology AG | Hitzehärtender Schaum |
| KR101714799B1 (ko) | 2008-12-30 | 2017-03-09 | 아르퀼 인코포레이티드 | 치환된 5,6-디히드로-6-페닐벤조［ｆ］이소퀴놀린-2-아민 화합물 |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| JP5868168B2 (ja) | 2011-12-28 | 2016-02-24 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| WO2024258849A2 (en) * | 2023-06-13 | 2024-12-19 | The Trustees Of Indiana University | Small molecule antiviral drug treatment for human papillomavirus infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3753981A (en) * | 1970-07-15 | 1973-08-21 | Squibb & Sons Inc | 4-amino-2-styrylquinazoline compounds |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | ４−アミノキナゾリン誘導体およびそれを含有する医薬品 |
| WO1997020821A1 (en) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
| WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| CA2226058C (en) | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| EP0990653B1 (en) | 1997-05-30 | 2004-09-15 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazole derivatives |
| WO1999009986A1 (en) * | 1997-08-22 | 1999-03-04 | Kyowa Hakko Kogyo Co., Ltd. | 4-aminoquinazoline derivatives |
| NZ507760A (en) | 1998-03-26 | 2002-10-25 | Japan Tobacco Inc | Amide derivatives and nociceptin antagonists |
| CN1509184A (zh) * | 2001-03-19 | 2004-06-30 | �ձ���ҩ��ʽ���� | 止痒剂 |
-
2001
- 2001-03-30 US US10/239,750 patent/US6794389B2/en not_active Expired - Fee Related
- 2001-03-30 AU AU2001244688A patent/AU2001244688A1/en not_active Abandoned
- 2001-03-30 RU RU2002129100/04A patent/RU2268260C2/ru not_active IP Right Cessation
- 2001-03-30 EP EP01917752A patent/EP1306372B1/en not_active Expired - Lifetime
- 2001-03-30 CA CA002403605A patent/CA2403605A1/en not_active Abandoned
- 2001-03-30 DE DE60140545T patent/DE60140545D1/de not_active Expired - Lifetime
- 2001-03-30 AT AT01917752T patent/ATE449084T1/de not_active IP Right Cessation
- 2001-03-30 WO PCT/JP2001/002822 patent/WO2001072710A1/ja not_active Ceased
- 2001-03-30 CN CNB018075347A patent/CN1242993C/zh not_active Expired - Fee Related
- 2001-03-30 KR KR1020027012917A patent/KR20020083533A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2002129100A (ru) | 2004-02-27 |
| CA2403605A1 (en) | 2002-09-18 |
| DE60140545D1 (enExample) | 2009-12-31 |
| WO2001072710A1 (en) | 2001-10-04 |
| EP1306372B1 (en) | 2009-11-18 |
| RU2268260C2 (ru) | 2006-01-20 |
| EP1306372A4 (en) | 2004-03-17 |
| CN1242993C (zh) | 2006-02-22 |
| AU2001244688A1 (en) | 2001-10-08 |
| ATE449084T1 (de) | 2009-12-15 |
| CN1422255A (zh) | 2003-06-04 |
| US20030119855A1 (en) | 2003-06-26 |
| US6794389B2 (en) | 2004-09-21 |
| EP1306372A1 (en) | 2003-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20020083533A (ko) | 복소환 유도체 및 의약 | |
| US5589477A (en) | Pyrimidine derivatives and drugs | |
| JP2001502296A (ja) | ニューロペプチド―ｙリガンド | |
| NZ212856A (en) | Glutarimide derivatives and pharmaceutical compositions | |
| US20130116269A1 (en) | Cyclic n,n'-diarylthioureas and n,n'-diarylureas - androgen receptor antagonists, anticancer agent, method for preparation and use thereof | |
| TW201625618A (zh) | 抑制瞬時受體電位ａ１離子通道 | |
| RU2727194C2 (ru) | Гетероциклические соединения для лечения заболевания | |
| RU2300532C2 (ru) | Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция | |
| JPWO2002036577A1 (ja) | キナゾリン誘導体及び医薬 | |
| US20090275538A1 (en) | Arylmethylidene heterocycles as novel analgesics | |
| EP0221511B1 (en) | 2-aminosulfonyl-6-nitrobenzoic esters or amides, process for their preparation and pharmaceutical compositions containing them | |
| KR20030024919A (ko) | Ｎ-(3,5-디클로로-2-메톡시페닐)-4-메톡시-3-피페라진-1-일-벤젠술폰아미드 | |
| US7008955B2 (en) | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | |
| US4994464A (en) | Piperazinylpyrimidines as β-adrenergic receptor blockers | |
| EP0276057A2 (en) | Piperazinylpyrimidines as beta-adrenergic receptor blocking agents | |
| US9085539B2 (en) | Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof | |
| JP3830378B2 (ja) | アシルアミノシクロプロパン誘導体 | |
| CZ154097A3 (en) | Derivatives of 6-methoxy-1h-benzotriazole-5-carboxamide, process of their preparation and pharmaceutical compositions based thereon | |
| JP2798628B2 (ja) | 癲癇治療用の５−アミノカルボニル−５Ｈ−ジベンゾ［ａ，ｄ］シクロヘプテン−５，１０−イミン | |
| JPWO2001072710A1 (ja) | 複素環誘導体及び医薬 | |
| CN116535390B (zh) | pH敏感型4-酰胺哌啶类衍生物、药物组合物及其制备方法和应用 | |
| EP0171912B1 (en) | Pyrrolizidine compounds, methods for their production, and their uses | |
| CN101460474A (zh) | 作为钾通道开放剂的3,4-二氨基-3-环丁烯-1,2-二酮衍生物 | |
| US5041462A (en) | Novel substituted acetamide compounds and use as anti-allergic agents | |
| JP2585374B2 (ja) | イソオキサゾリン−３−オン関連化合物およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20020928 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |